The effect of niacin on serum phosphorus levels in dialysis patients

Indian Journal of Nephrology

Volumn 22, Issue 3, 2012, Pages 174-178

  Edalat Nejad, M ^a   Zameni, F ^a   Talaiei, A ^a  

^a ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hemodialysis; hyperphosphatemia; niacin; niacinamide; nicotinic acid

Indexed keywords

ALUMINUM HYDROXIDE; CALCIUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PARATHYROID HORMONE; PHOSPHORUS; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HUMAN; LONG TERM CARE; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRESCRIPTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84864482531     PISSN: 09714065     EISSN: 19983662     Source Type: Journal    
DOI: 10.4103/0971-4065.98751     Document Type: Article

References (13)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1-130.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
3. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys 1955;54:558-9.
4. Katai K, Tanaka H, Tatsumi S, Fukunaga Y, Genjida K, Morita K, et al. Nicotinamide inhibits sodium dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 1999;14:1195-201.
5. Eto N, Miyata Y, Ohno H, Yamashita T. Nicotinamide prevents the development of hyperphosphatemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenininduced renal failure. Nephrol Dial Transplant 2005;20:1378-84.
6. Morrow JD, Parsons WG 3rd, Roberts LJ 2nd. Release of markedly increased quanitites of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989;38:263-74.
7. Parhofer KG. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc Health Risk Manag 2009;5:901-8.
8. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004;65:1099-104.
9. Muller D, Mehling H, Otto B, Bergmann-Lips R, Luft F, Jordan J, Kettritz R. Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol 2007;2:1249-54.
10. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1131-8.
11. Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RN. Extended release nicotinic acid-a novel oral agent for phosphate control. Int Urol Nephrol 2006;38:171-4.
12. Restrepo Valencia CA, Cruz J. Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia. Nefrologia 2008;28:61-6.
13. Maccubbin D, Tipping D, Kuznetsova O, Hanlon WA, Bostom AG. Hypophosphatemic effect of niacin in patients without renal failure: A randomized trial. Clin J Am Soc Nephrol 2010;5:582-9.